Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Phase III Study of TO-210 in Acne Vulgaris
jRCT2031250482Phase 3Active, not recruiting
- Sponsor
- Torii Pharmaceutical
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tapinarof in acne vulgaris, sponsored by Torii Pharmaceutical. Primary endpoint: Safety. Started Nov 2025; status: active, not recruiting.
02
Drugs
tapinarof
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on jRCT2031250482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250482.